摘要
目的研究脱嘌呤脱嘧啶核酸内切酶(APE1)和细胞增殖抗原标记物Ki67蛋白在胃癌组织中的表达及其临床意义。方法选取未经术前放、化疗的胃癌标本99例,用免疫组织化学EnVision法检测两组APE1和Ki67基因的表达,分析其与胃癌临床病理特征的关系。结果胃癌组织APE1和Ki67蛋白的阳性表达率分别为63.6%(63/99)和64.6%(64/99);APE1和Ki67蛋白的阳性表达率与胃癌组织淋巴结转移均密切相关(P<0.05);APE1的表达亦与胃癌组织浸润深度相关(P<0.05);胃癌组织中APE1和Ki67蛋白两者的表达呈正相关(r=0.319,P<0.01)。结论APE1可能是预测胃癌组织浸润、转移有用的指标;联合检测APE1和Ki67蛋白可作为判断胃癌预后和筛选高危转移患者的有效指标。
Objective To investigate the expression and endonuclease（APE1） and Ki67 in gastric carcinoma. Methods significance of apurinic/aprimidinic The expressions of APE1 and Ki67 were detected by EnVision immunohistochemistry in paraffin-embedded samples from 99 cases with gastric carcinoma, who were not treated with radiotherapy or chemotherapy. The correlation of APE1 and Ki67 expressions with the clinicophathologic lectures of gastric carcinoma was analyzed. Results The positive expression rates of APE1 and Ki67 proteins in gastric carcinoma were 63.6%（63/99） and 64. 60% （64/99）, respectively. The expressions of APE1 and Ki67 were closely correlated to lymph node metastasis （P〈0.05）. The expression of APE1 was correlated to the depth of invasion （P〈0. 05）. The expression of APE1 was positively correlated with that of Ki67 （r=0. 319, P〈0. 01）. Conclusion APE1 protein could be a marker to predict gastric cancer invasion and metastasis process. Combined detection of APE1 and Ki67 expressions can be taken as an indicator for evaluating the prognosis and screeniniz the high risk for metastasis in the casps with gastric cancer.
出处
《江苏医药》
CAS
CSCD
北大核心
2012年第19期2290-2292,共3页
Jiangsu Medical Journal
